Chia Tai Tianqing has announced the successful completion of a Phase I clinical study for its in-house developed Category 1 drug, TQA3038 (siRNA), with plans to advance to subsequent clinical trials for the treatment of chronic hepatitis B virus (HBV) in the near future.
TQA3038 is a GalNAc-conjugated siRNA drug that is designed to target and accumulate in the liver. Once in the liver, it effectively degrades the specified RNA, inhibiting the translation of proteins essential for HBV replication and demonstrating potent antiviral activity both in vivo and in vitro.- Flcube.com
